1416 Results

People

  1. Motzer
    Motzer
  2. Vickers
    Vickers
  3. Hudis
    Hudis
  4. Norton
    Norton
  5. Saltz
    Saltz
  6. O'Reilly
    O'Reilly
  7. Mao
    Mao
  8. Morris
    Morris
  9. Seidman
    Seidman
  10. Kris
    Kris

Groups

  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)
  7. Hematologic Malignancies, Division of (169)
  8. Genitourinary Oncology Service (160)
  9. Center for Hematologic Malignancies (142)
  10. Gastrointestinal Oncology Service (126)
  1. "randomized controlled trial"
Formats
  1. Journal Article (1353)
  2. Review (19)
  3. Conference Paper (17)
  4. Editorial (9)
  5. Correspondence (5)
  6. Research Letter (5)
  7. Meeting Abstract (4)
  8. Guidelines (3)
  9. Book Section (1)
Groups
  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)

More Groups

People
  1. Robert Motzer (83)
  2. Andrew Vickers (48)
  3. Larry Norton (34)
  4. Clifford Hudis (33)
  5. Leonard Saltz (32)
  6. Eileen O'Reilly (25)

More People

Years
  1. 2025 (63)
  2. 2024 (165)
  3. 2023 (110)
  4. 2022 (81)
  5. 2021 (39)
  6. 2020 (51)

More Years

Publications
  1. Journal of Clinical Oncology (164)
  2. New England Journal of Medicine (65)
  3. Lancet Oncology (46)
  4. Cancer (42)
  5. Clinical Cancer Research (42)
  6. European Urology (26)

More Publications

Publishers
  1. Elsevier Inc. (187)
  2. American Society of Clinical Oncology (170)
  3. Elsevier Science, Inc. (138)
  4. Springer (79)
  5. Lippincott Williams & Wilkins (72)
  6. Wiley Blackwell (71)

More Publishers

Results (1416)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: A matching-adjusted indirect comparison
    Journal Article

    Rugo, H. S.; Harmer, V.; O’Shaughnessy, J.; Jhaveri, K.; Tolaney, S. M.; Cardoso, F.; Bardia, A.; Maheshwari, V. K.; Tripathi, S.; Haftchenary, S.; more...
    Therapeutic Advances in Medical Oncology (2023)

    Fulltext@MSK | Save
  • Ide-cel or standard regimens in relapsed and refractory multiple myeloma
    Journal Article

    Rodriguez-Otero, P.; Ailawadhi, S.; Arnulf, B.; Patel, K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N.; Costa, L. J.; Vij, R.; more...
    New England Journal of Medicine (2023)

    Fulltext@MSK | Save
  • Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): A double-blind, randomised, phase 3 trial
    Journal Article

    Motzer, R. J.; Russo, P.; Grünwald, V.; Tomita, Y.; Zurawski, B.; Parikh, O.; Buti, S.; Barthélémy, P.; Goh, J. C.; Ye, D.; more...
    Lancet (2023)

    Fulltext@MSK | Save
  • A first-in-human phase I study of milademetan, an MDM2 inhibitor, in patients with advanced liposarcoma, solid tumors, or lymphomas
    Journal Article

    Gounder, M. M.; Bauer, T. M.; Schwartz, G. K.; Weise, A. M.; LoRusso, P.; Kumar, P.; Tao, B.; Hong, Y.; Patel, P.; Lu, Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): A randomized, open-label, phase III trial
    Journal Article

    Dimopoulos, M. A.; Oriol, A.; Nahi, H.; San-Miguel, J.; Bahlis, N. J.; Usmani, S. Z.; Rabin, N.; Orlowski, R. Z.; Suzuki, K.; Plesner, T.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: A NRG oncology randomized study
    Journal Article

    Tewari, K. S.; Sill, M. W.; Birrer, M. J.; Penson, R. T.; Huang, H.; Moore, D. H.; Ramondetta, L. M.; Landrum, L. M.; Oaknin, A.; Reid, T. J.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial
    Journal Article

    Praiss, A. M.; Zhou, Q.; Iasonos, A.; Moukarzel, L.; Dessources, K.; Soldan, K.; Su, K.; Sonoda, Y.; Roche, K. L.; Gardner, G. J.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
    Journal Article

    Robson, M. E.; Im, S. A.; Senkus, E.; Xu, B.; Domchek, S. M.; Masuda, N.; Delaloge, S.; Tung, N.; Armstrong, A.; Dymond, M.; more...
    European Journal of Cancer (2023)

    Fulltext@MSK | Save
  • Bolus versus continuous intravenous delivery of doxorubicin in soft-tissue sarcomas: Post hoc analysis of a prospective randomized trial (SARC021/TH CR-406)
    Journal Article

    Cranmer, L. D.; Lu, Y.; Heise, R. S.; Ballman, K. V.; Loggers, E. T.; Pollack, S. M.; Wagner, M. J.; Reinke, D. K.; Schöffski, P.; Tap, W. D.
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Effect of jianpi bushen formula for colon cancer patients who underwent adjuvant chemotherapy: Statistical analysis plan for a multicenter trial
    Journal Article

    Zhao, R.; Cao, H.; Sun, L.; Zhang, T.; Xu, Y.; Yan, S.; Mao, J.; Liu, J.; Fei, Y.; Yang, Y.
    Journal of Traditional Chinese Medical Sciences (2023)

    Fulltext@MSK | Save